The European Medicines Agency will hold a press conference at 4 pm this Wednesday to strengthen the surveillance of AstraZeneca’s Covid-19 vaccine (renamed Vaxzeria).
The European Medicines Agency (EMA) announced on Wednesday that it will hold a press conference at 4 pm to strengthen the surveillance of AstraZeneca’s Covid-19 vaccine and possible links with blood clot formation.
In this case, the FDA Pharmacovigilance Risk Assessment Committee must draw conclusions on its latest analysis of thromboembolic disease (rare but serious) cases that have recently been renamed in adults.
An EMA official said in an interview published on Tuesday by the Italian daily Il Messaggero that a link has been established between the Anglo-Swedish laboratory vaccine and the occurrence of venous thrombosis, especially cerebral thrombosis.
The balance of return and risk is generally positive
Following the statement made by the head of the Covid-19 vaccine strategy, EMA stated in a press release that its verification has not yet been completed.
The World Health Organization (WHO) stated that the vaccine’s benefit-risk balance assessment is not expected to undergo any changes, which is largely positive.
The EMA summary previously released on March 31 covered 258 serious thromboembolic diseases among nearly 20 million first injections in the European Union and the United Kingdom, including 45 deaths.
The agency then concluded that to date, there is no proven link between the vaccine developed in collaboration with Oxford University and the risk of thrombosis.
At this stage, his work has not found possible risk factors that are conducive to the appearance of atypical thrombosis (thrombosis), which may migrate to blocked blood vessels in certain organs (embolism).